University Hospitals Seidman Cancer Center becomes first in the United States to implement Akesis Inc. innovative Galaxy RTI device for patient treatment

CLEVELAND – Akesis, Inc. (Akesis), a leader in cutting-edge radiation oncology technology, has formed a groundbreaking collaboration with University Hospitals Seidman Cancer Center, a nationally recognized cancer care institution. Through this alliance, UH Seidman Cancer Center becomes the first medical center in the United States to implement the innovative Akesis Galaxy RTi device for patient treatments, while also serving as the flagship site for research and clinical demonstration of this advanced technology.

As part of the agreement, UH Seidman Cancer Center will incorporate the Galaxy RTi into the stereotactic radiosurgery (SRS) program, aiming to set new benchmarks in precision treatment and patient outcomes. The center will also provide healthcare professionals worldwide with the opportunity to engage directly with the system’s capabilities through on-site demonstrations and research initiatives.

"We are thrilled to reach this significant milestone with University Hospitals Seidman Cancer Center," said Lien Pham, VP and COO of Akesis. "The Galaxy RTi represents a major leap forward in SRS technology, and we believe this collaboration will maximize its impact, benefiting patients worldwide."

Dr. Daniel Spratt, Chair of Radiation Oncology at UH Seidman Cancer Center in Cleveland, Associate Chief Scientific Officer of University Hospitals Cleveland Medical Center and Vincent K. Smith Chair in Radiation Oncology, expressed his excitement about the collaboration, stating, "At UH Seidman Cancer Center, we are committed to leading the adoption of breakthrough technologies that advance patient care. This collaboration with Akesis underscores our mission to transform cancer treatment and establish new standards in the field."

This initiative is set to accelerate the integration of next-generation radiation technologies, foster a culture of innovation, and elevate the standard of care. Together, Akesis and UH Seidman Cancer Center aim to improve patient outcomes, enhance treatment efficiency, and contribute to the evolution of global cancer care.

Dr. Prashant Vempati, Director of CNS Radiation Oncology and Director of Radiosurgery in Radiation Oncology at UH Seidman Cancer Center, and Dr. Tiffany Hodges, Neurosurgeon, Peter D. Cristal Endowed Chair in Neurosurgery and Surgical Director of the Brain Tumor Center, UH Seidman Cancer Center offered a joint statement: “We are very excited to bring this incredibly innovative cutting-edge technology to UH Seidman Cancer Center. Akesis is more than just a radiosurgery machine—it represents our deep commitment to patients and community.  It’s a promise of healing, and of lives transformed through the power of precision, innovation, and compassion.”